Literature DB >> 12721395

Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs).

Ronald A Simon1, Jennifer Namazy.   

Abstract

BACKGROUND: Aspirin can provoke reactions ranging from respiratory to cutaneous in those susceptible individuals. There has been particular attention looking at the role of cyclooxygenase enzymes and 2 and their role in aspirin exacerbated respiratory disease.
OBJECTIVE: Patients who present with a spectrum of allergic and pseudoallergic reactions to aspirin pose a special challenge for the physician. This article discusses proposed classification system, clinical manifestations, pathogenesis of disease, and current treatment options of aspirin related disease.
METHODS: Relevant articles in the medical literature were. derived from searching the MEDLINE database. Sources also include review articles, randomized control trials, and standard textbooks of allergy and immunology.
RESULTS: Aspirin-exacerbated respiratory disease remains a complex, heterogeneous disease with manvaried clinical presentations. There have been many advances in trying to elucidate the pathogenesis of this disease. The classification system presented will provide greater ease when reading the literature and communicating with one another. Oral aspirin challenge remains the diagnostic test of choice for both respiratory and cutaneous reactions. Aspirin desensitization is an option for those with refractory respiratory disease or who require aspirin for other medical conditions.
CONCLUSIONS: This review discusses the challenges in classification, diagnosis and treatment of those patients with a sensitivity to aspirin. Special attention is made to the possible mechanisms mediating disease progression and how specific. Therapies, such as the leukotriene modifiers may be helpful.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721395     DOI: 10.1385/CRIAI:24:3:239

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  47 in total

1.  Tryptase and histamine release during aspirin-induced respiratory reactions.

Authors:  J V Bosso; L B Schwartz; D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1991-12       Impact factor: 10.793

2.  Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

Authors:  B Dahlén; E Nizankowska; A Szczeklik; O Zetterström; G Bochenek; M Kumlin; L Mastalerz; G Pinis; L J Swanson; T I Boodhoo; S Wright; L M Dubé; S E Dahlén
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

Review 3.  The cyclooxygenase theory of aspirin-induced asthma.

Authors:  A Szczeklik
Journal:  Eur Respir J       Date:  1990-05       Impact factor: 16.671

Review 4.  Drug- and chemical-induced aseptic meningitis: a review of the literature.

Authors:  J S Marinac
Journal:  Ann Pharmacother       Date:  1992-06       Impact factor: 3.154

5.  Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin.

Authors:  W W Pleskow; D D Stevenson; D A Mathison; R A Simon; M Schatz; R S Zeiger
Journal:  J Allergy Clin Immunol       Date:  1983-06       Impact factor: 10.793

6.  Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge.

Authors:  U R Juergens; S C Christiansen; D D Stevenson; B L Zuraw
Journal:  J Allergy Clin Immunol       Date:  1992-10       Impact factor: 10.793

7.  Idiosyncrasy to pyrazolone drugs.

Authors:  G Czerniawska-Mysik; A Szczeklik
Journal:  Allergy       Date:  1981-08       Impact factor: 13.146

8.  Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.

Authors:  K Sladek; R Dworski; J Soja; J R Sheller; E Nizankowska; J A Oates; A Szczeklik
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405

9.  Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.

Authors:  P Sestini; L Armetti; G Gambaro; M G Pieroni; R M Refini; A Sala; A Vaghi; G C Folco; S Bianco; M Robuschi
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

10.  Inhibition of monocyte leukotriene B4 production after aspirin desensitization.

Authors:  U R Juergens; S C Christiansen; D D Stevenson; B L Zuraw
Journal:  J Allergy Clin Immunol       Date:  1995-08       Impact factor: 10.793

View more
  5 in total

1.  Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs.

Authors:  L Gallelli; M Colosimo; D Pirritano; M Ferraro; S De Fazio; N M Marigliano; G De Sarro
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 2.  Cutaneous Drug Reactions in the Elderly.

Authors:  James W S Young; Neil H Shear
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 4.271

3.  Adverse drug reactions of nonsteroidal anti-inflammatory drugs in orthopedic patients.

Authors:  Alpa Pragnesh Gor; Miti Saksena
Journal:  J Pharmacol Pharmacother       Date:  2011-01

Review 4.  Activities and Molecular Mechanisms of Diterpenes, Diterpenoids, and Their Derivatives in Rheumatoid Arthritis.

Authors:  Muhammad Torequl Islam; Cristina Quispe; Jesús Herrera-Bravo; Md Mizanur Rahaman; Rajib Hossain; Chandan Sarkar; Md Abdur Raihan; Md Mashrur Chowdhury; Shaikh Jamal Uddin; Jamil A Shilpi; João Marcelo de Castro E Sousa; Ana Amélia de Carvalho Melo-Cavalcante; Mohammad S Mubarak; Javad Sharifi-Rad; Daniela Calina
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-25       Impact factor: 2.629

5.  Assessing the negative impact of phenyl alkanoic acid derivative, a frequently prescribed drug for the suppression of pain and inflammation, on the differentiation and proliferation of chondrocytes.

Authors:  Seyit Ali Gumustas; İbrahim Yilmaz; Mehmet Isyar; Duygu Yasar Sirin; Ahmet Guray Batmaz; Ali Akin Ugras; Kadir Oznam; Zafer Ciftci; Mahir Mahirogullari
Journal:  J Orthop Surg Res       Date:  2016-06-30       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.